Microba Life Sciences Limited (ASX: MAP) has executed agreements with SYNLAB International GmbH affiliate organisations Referans M-B Saglik Labopratuvar and SYNLAB czech s.r.o., to distribute Microba’s testing technology into Türkiye and Czech Republic respectively.
We continue to progress distribution expansion with SYNLAB, Europe’s largest medical diagnostics company, to drive our testing into the hands of clinicians and patients across Europe,” Microba’s Senior Vice President – Services, Bernie Woodcroft said.
“Adding Türkiye and Czech Republic is another positive step forward in the global distribution expansion of Microba’s testing services”.
In 2020, Microba entered into a master agreement with SYNLAB International GmbH and an agreement with SYNLAB Diagnosticos Globales to deliver Microba’s testing to Healthcare Providers in Spain, with an option to formalise distribution agreements across their affiliate organisations, which operate in 36 countries.
With positive sales and customer feedback in Spain, in October 2022 SYNLAB further activated their rights through an amendment to the master agreement with Microba to pursue formal expansion into additional countries across Europe and Latin America. Aligned to this, in December a first group of new agreements were signed with SYNLAB affiliate organisations for Italy and Portugal respectively, which have now been operationalised and achieved first sales.
Additional agreements have now been signed with SYNLAB affiliate organisations for Türkiye and Czech Republic respectively, which provide them with non-exclusive distribution rights out to 31 December 2028.
Entry into both Türkiye and Czech Republic, represents another positive advancement in distribution with Europe’s largest medical diagnostics company. Further affiliate country agreements are anticipated to be completed in the near term to continue this expansion activity with SYNLAB.
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers.
